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ABSTRACT
Background Charles Bonnet Syndrome (CBS) is widely
considered a transient condition without adverse
consequence, questioning the need for treatment. Yet,
while this view may be true of the majority of people
with CBS, it is recognised that some have negative
experiences and outcomes. Here, we attempt to better
understand negative outcome CBS and the factors that
influence it.
Methods 4000 members of the Macular Society were
sent a structured questionnaire covering the
phenomenology of CBS, its prognosis and impact,
symptom reporting, patient knowledge and sources of
information.
Results 492 people with CBS were identified. Kaplan–
Meier analysis suggested 75% had CBS for 5 years or
more. Thirty-two per cent had negative outcome. Factors
associated with negative outcome were: (1) frequent,
fear-inducing, longer-lasting hallucination episodes, (2)
one or more daily activities affected, (3) attribution of
hallucinations to serious mental illness, (4) not knowing
about CBS at the onset of symptoms. Duration of CBS or
the type of content hallucinated were not associated
with negative outcome.
Conclusions CBS is of longer duration than previously
suspected with clinically relevant consequences in a third
of those affected. Interventions that reduce the
frequency, duration or fear of individual hallucination
episodes and education prior to hallucination onset may
help reduce negative outcome.
INTRODUCTION
Charles Bonnet’s description of his grandfather’s
visual hallucinations1 2 lies at the boundary of what
might be considered a ‘clinical’ condition. Bonnet
focussed on positive aspects of the experience, such
as the pleasure and intellectual curiosity hallucina-
tions gave, and the fact they were not associated
with psychological or cognitive problems. His
grandfather had significant visual impairment,
plausibly related to age-related macular disease
(AMD),3 but there was no suggestion the hallucina-
tions themselves were an illness or that treatment
would have been necessary or appropriate.
Furthermore, the hallucinations resolved within a
few months, so that any problems would have been
short-lived. Reawakened interest in Charles Bonnet
Syndrome (CBS) has done little to dispel this view
with consistent reports that the majority of patients
with CBS do not find it troublesome.4–8 Yet, a
sizable minority report a range of negative experi-
ences and outcomes. Compared to patients with
the same degree of visual loss without hallucina-
tions, patients with CBS have decreased measures
of quality of life and functional ability,9 and some
fear being labelled as having serious mental illness.7
Around a third find the hallucinations themselves
an unpleasant or disturbing experience.5–8 CBS
thus covers a spectrum of outcomes, one end cele-
brated by Bonnet in his description of hallucina-
tions as ‘playthings of the brain’, the other a
predominantly negative outcome characterised by
distress, stigma and reduced quality of life. Given
that this latter group is potentially large (between
16 000 and 100 000 people in the UK based on a
∼500 000 population with late AMD10 and CBS
prevalence of 10–60%11) it is becoming increas-
ingly important to better understand what factors
lead to negative outcome and how people with
negative experiences of CBS differ from those that
do not find CBS distressing. Furthermore, there is
emerging evidence that CBS may not be as transi-
ent as traditionally held. One study has reported
hallucinations continuing for 4 years or more in
45% of people with CBS,8 while another found
41% of people with CBS had an estimated minimal
average duration of 8 years (minimal as hallucina-
tions were ongoing at the end of the study).6 It is
difficult to dismiss CBS as a clinical irrelevance if it
results in troubling symptoms that persist for many
years for a large group of people. Here, we set out
to re-evaluate the prognosis of CBS, and character-
ise factors associated with its negative outcome in a
large-scale survey of members of the Macular
Society, a UK charity for people affected by central
vision loss that provides practical and emotional
support, campaigns for improvements in services
and funds research.
METHODS
Four thousand members of the Macular Society
were selected at random from the membership
database (database n=10 847 after excluding
members surveyed the previous year) using cam-
paign management software (NFP CARE, Advance
computer software group). Those selected were
sent a structured questionnaire in October 2012
covering CBS: demographics, risk factors, phenom-
enology, duration/prognosis, (using items derived
from the Institute of Psychiatry Visual
Hallucinations Interview8) impact on daily living
and wellbeing, reporting of symptoms and sources
of information (see online supplementary material
for questionnaire content). Questionnaires were
returned by post. Members unable to read the
questionnaire were offered support in completing it
by telephone. The study was approved by the
King’s College London, Psychiatry, Nursing and
Midwifery Research Ethics subcommittee (PMN/
11/12-64). All participants gave informed consent.
Categorical variables were compared using χ2 tests
with Bonferroni correction where appropriate.
Continuous variables were examined using analysis
of variance (ANOVA) models. Duration of CBS was
calculated from the month/year of CBS onset and
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month/year of last hallucination, with a resolution of 3 months,
and analysed using the Kaplan-Meier method,12 with cessation
of hallucinations as the outcome event of interest. To avoid
inflating the estimate of duration through rounding error, if no
month was specified for month/year of onset, the end of the
year was used.
RESULTS
A total of 1254 surveys were returned by members who
reported a diagnosis of macular disease (31% of questionnaires
sent). Of these, 39% (n=492) had experienced hallucinations of
patterns (63%), faces (39%), objects (39%), figures (36%) and
animals (22%) and had been told they had, or judged them-
selves to have had, CBS. Typical hallucinations were of short
duration, lasting either minutes (44%) or seconds (34%). When
judged at their worst, hallucinations could occur weekly (30%),
monthly (21%), daily (22%) or constantly (13%). Figure 1
shows different categories of emotional response (more than
one could be selected) at the onset of CBS (dark grey bars) and
at the time of the questionnaire (light grey bars). At CBS onset,
38% reported one or more of responses: startling, terrifying
and frightening (pooled as ‘fear-inducing’), reducing to 8% at
the time of the questionnaire. Forty-six per cent reported that
CBS had an effect on daily activities, selecting responses: televi-
sion watching (24%), moving about (14%), cooking (8%) and
sleeping (14%) with free-text answers of: reading, driving and
relaxing. Only 7% had not told anyone about CBS. Forty-seven
per cent had discussed it with a medical professional with
around a third of these selecting responses indicating the profes-
sional was unsure or did not know about the diagnosis.
Sixty-seven per cent had not heard of CBS at symptom onset
and attributed the hallucinations to one or more of responses:
sight loss (50%), mental illness (11%), Alzheimer’s disease (5%)
or unknown (40%) with free text answers: side-effects of medi-
cation, physical illness and real events. Sixty-three per cent were
relieved and/or reassured by receiving information on CBS.
Prognosis of CBS
Figure 2 shows the Kaplan–Meier plot of CBS duration. The
method takes into account the fact that many of the participants
were still having hallucinations at the time of the survey, so that
the duration of their CBS is unknown (censored data).
However, the large sample size meant that ∼100 CBS resolution
events were available from which to estimate the duration (sur-
vival) function. Two measures of symptom resolution were
used. One was derived from the questionnaire item asking
whether CBS had stopped or was on-going at the time of the
questionnaire (figure 2A). Using this measure, 88% of the
sample (95% CI 85% to 92%) had CBS for 2 years or more,
resolving in only 25% at 9 years. We recognised that it might be
difficult to judge whether CBS has resolved if hallucinations
only occur infrequently (eg, every 6 months). We therefore
repeated the analysis applying an arbitrary definition of reso-
lution as having no hallucinations in the 3 months prior to the
questionnaire (figure 2B). The prognosis at 2 years was the same
using this definition (87% with ongoing CBS; 95% CI 83% to
90%) but the time for 25% to resolve reduced to 5.75 years.
Negative outcome CBS
While the majority of people with CBS felt it had no real effect
on their life (60%), a subset judged it to have a fairly negative
(25%) or very negative (8%) effect, and 6% reported a fairly
pleasant or very pleasant effect (1%). We collapsed these
responses into three outcome valencies: negative (fairly and
very negative, n=156), positive (fairly and very pleasant, n=36)
and neutral (n=289). Negative outcome was not associated with
gender or diagnosis (wet, dry, wet and dry AMD; p>0.05). It
was associated with longer-duration hallucination episodes
(χ2=38.9, p<0.00 001) and more frequent hallucination epi-
sodes (χ2=31.7, p=0.0001). There was no difference in mean
overall duration of CBS (CBS onset to cessation) for subgroups
with negative outcome (mean duration 2.7±2.0 years), positive
outcome (1.9±1.3 years) and neutral outcome (3.3±3.9 years)
(F2,75=0.452; p=0.638—censored data excluded). Negative
outcome was not associated with a particular type of hallucin-
ation content (pcorr>0.05 for patterns, faces, people, animals
and objects). Fear-inducing hallucinations at CBS onset were
associated with negative outcome (45% of the subgroup with
fear-inducing hallucinations at onset had negative outcome vs
25% of the subgroup without fear-inducing hallucinations;
χ2=23.2, pcorr=0.00001). CBS affecting one or more daily
activities was associated with negative outcome (52% of the sub-
group with an activity affected had negative outcome vs 16% of
the subgroup with no activities affected, χ2=75.3,
p<0.000001). Attributing CBS to mental illness or, at trend sig-
nificance, Alzheimer’s disease was associated with negative
outcome (58% of the subgroup attributing CBS to mental
illness had negative outcome vs 30% of the subgroup not attrib-
uting CBS to mental illness, χ2=12.0, pcorr=0.01). Attributing
CBS to sight loss was not associated with negative outcome
(χ2=0.087, pcorr>0.05). Lack of prior knowledge about CBS at
symptom onset was associated with negative outcome (25% of
the subgroup familiar with CBS at onset had negative outcome
vs 35% of the subgroup unfamiliar with CBS at onset; χ2=6.4,
p=0.04). There was also a trend association between the quality
of information given by medical professional and negative
outcome (47% of the subgroup not given a clear account, had
negative outcome vs 36% of the subgroup given a clear account;
χ2=4.5, p=0.10).
DISCUSSION
This is the largest phenomenological survey of CBS reported to
date, with 492 people identified, compared to an average of 42
people (range 4–150) in previous surveys.4–9 13–21 The scaling
Figure 1 Emotional responses to Charles Bonnet Syndrome
hallucinations. Bars indicate % of hallucinators reporting each emotion.
Dark grey indicates emotions at the onset of symptoms, light grey at
the time of the questionnaire. χ2 corrected for multiple comparisons
***pcorr<0.001; **pcorr<0.01; NS pcorr>0.05.
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in sample size allows us to explore issues less amenable to inves-
tigation in smaller studies due to their limitations of statistical
power. Although our sample is derived from members of a vol-
untary society, the phenomenology of the hallucinations
reported (ie, relative frequency of each content category, distri-
bution of emotional responses, temporal characteristics etc)
match those of previous surveys in clinical settings giving us
confidence the findings are representative of CBS as a whole.
How long does CBS continue?
CBS continued for 5 years or more in 75% of the sample. This
seems inconsistent with previous longitudinal studies suggesting
28% recovery at 1 year 22 or an average duration of 18
months.23 However, the former study relates to resolution over
the course of a year without specifying prior duration of CBS,
while the latter study does not take into account participants
with on-going CBS (censored observations). Our study indicates
the typical duration of CBS is far longer than these estimates,
and questions the traditional view that CBS is a transient condi-
tion. It is possible our estimate is biased by people with shorter-
duration CBS choosing not to participate in the survey.
However, this seems unlikely, as the estimate of CBS prevalence
based on the total number of questionnaires sent (12%) is
similar to previous prevalence estimates for ophthalmic popula-
tions (∼10%)3 suggesting we were not missing a large propor-
tion of respondents.
Factors influencing negative outcome CBS
The 32% prevalence of negative outcome in our sample is
similar to that described in previous studies.4 5 21 Since our def-
inition of negative outcome CBS is derived from self-report,
without formal measures of psychopathology, well-being, or
quality of life, its true clinical significance remains to be deter-
mined. However, a higher proportion of the negative outcome
CBS subgroup sought medical advice suggesting it has clinical
implications (61% of the negative outcome subgroup sought
medical advice vs 45% of the neutral or 44% of the positive
subgroup, χ2=10.3 p=0.006). Some of the factors associated
with negative outcome were linked to the hallucinations them-
selves (eg, how long a typical hallucination lasts and whether it
induced fear) while others related to knowledge of CBS and
quality of information. We explored the relative importance of
each hallucination-related and education-related factor as a
target for theoretical intervention by calculating the expected
reduction in negative outcome for each intervention (table 1).
There was a clear advantage for interventions targeting
hallucination-related factors over education-related factors. This
may reflect the fact that Macular Society members were well
informed at baseline, with only 13% unfamiliar with CBS prior
to the questionnaire. In comparison, 71% of the clinical sample
reported by Abbott et al20 had no knowledge of CBS prior to
their study. It is thus likely that information about CBS prior to
symptom onset will have a greater impact on negative outcome
in the wider clinical population than found here. Replicating
Figure 2 Kaplan–Meier plots of Charles Bonnet Syndrome (CBS) duration. (A) The proportion of the sample with CBS each year after onset based
on self-report of CBS resolution. The vertical dashes indicate censored observations. (B) The proportion of the sample with CBS each year after onset
with CBS resolution defined as an absence of hallucinations in the 3 months prior to the questionnaire.
Table 1 Reduction in proportion of negative outcome CBS from
base rate (32%) using hypothetical interventions indicated
Treatment
category Theoretical treatment target
% Reduction in
negative outcome
Hallucination-related Reduction of duration of
hallucination episodes to
seconds
44
Reduction of hallucination
frequency to monthly
47
Resolution of fearful emotional
responses
24
No limitation of activities 52
Education-related CBS awareness at symptom
onset
20
No attribution of CBS to mental
illness
6
Improved clarity of explanation 2
CBS, Charles Bonnet Syndrome.
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findings of a previous study,24 less than half of those with CBS
sought medical advice. This low rate of advice-seeking sets a
limit on the ability to reduce negative outcome by targeted
training of medical professionals.
An unexpected finding was the lack of association between
overall duration of CBS and negative outcome. This may reflect
a habituation to CBS over time, as supported by the reduction
in fear-inducing hallucinations from symptom onset to the time
of the questionnaire. Consistent with previous reports,4 23 some
participants suggested the frequency and duration of individual
hallucination episodes reduced with time so that they no longer
considered them a problem. For other participants, hallucina-
tions ceased for a period but returned with subsequent progres-
sion of their macular disease. Such observations highlight the
difficulty in defining when CBS resolves and question the rele-
vance of CBS cessation as an endpoint for clinical trials.
CONCLUSIONS
What are the clinical implications of the findings? It is clear that
CBS can no longer be considered a homogeneous, transient con-
dition. For most people with CBS, symptoms continue for many
years with negative consequences in around a third. This
changes CBS from a symptom that can be largely ignored by
clinical services to one that needs further characterisation to
identify those with negative outcome and offer appropriate
interventions. The low priority given to CBS research to date
means there is currently an absence of evidence as to what treat-
ments might be effective. Our study suggests an alternative treat-
ment goal to cessation of hallucinations might be to target
negative outcome, reducing the duration, frequency, fear associ-
ation and interference with activities of ongoing hallucinations
to result in a more benign form of CBS. The findings also
suggest negative outcome might be preventable, and the need
for trials to examine the effectiveness of information/psychoedu-
cation prior to the onset of hallucinations. The era of CBS as an
incidental curiosity has ended; for those with negative outcome,
CBS now lies unequivocally within the clinical domain.
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